Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis.

van Bilsen JH, van Dongen H, Lard LR, van der Voort EI, Elferink DG, Bakker AM, Miltenburg AM, Huizinga TW, de Vries RR, Toes RE.

Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17180-5. Epub 2004 Nov 29.

2.

An HLA-DRB1-derived peptide associated with protection against rheumatoid arthritis is naturally processed by human APCs.

Snijders A, Elferink DG, Geluk A, van Der Zanden AL, Vos K, Schreuder GM, Breedveld FC, de Vries RR, Zanelli EH.

J Immunol. 2001 Apr 15;166(8):4987-93.

3.

Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions.

Vos K, Miltenburg AM, van Meijgaarden KE, van den Heuvel M, Elferink DG, van Galen PJ, van Hogezand RA, van Vliet-Daskalopoulou E, Ottenhoff TH, Breedveld FC, Boots AM, de Vries RR.

Rheumatology (Oxford). 2000 Dec;39(12):1326-31.

PMID:
11136874
4.

Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients.

de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, Casanova JL, Ottenhoff TH.

Science. 1998 May 29;280(5368):1435-8.

5.

Liposome-mediated peptide loading of MHC-DR molecules in vivo.

t Hart BA, Elferink DG, Drijfhout JW, Storm G, van Blooijs L, Bontrop RE, de Vries RR.

FEBS Lett. 1997 Jun 2;409(1):91-5.

6.

Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates.

Geluk A, Elferink DG, Slierendregt BL, van Meijgaarden KE, de Vries RR, Ottenhoff TH, Bontrop RE.

J Exp Med. 1993 Apr 1;177(4):979-87.

7.
9.

DR3-restricted T cells from different HLA-DR3-positive individuals recognize the same peptide (amino acids 2-12) of the mycobacterial 65-kDa heat-shock protein.

Van Schooten WC, Elferink DG, Van Embden J, Anderson DC, De Vries RR.

Eur J Immunol. 1989 Nov;19(11):2075-9.

PMID:
2480902
10.

Polymorphism and complexity of HLA-DR: evidence for intra-HLA-DR region crossing-over events.

Bontrop RE, Tilanus MG, Mikulski MM, Elferink DG, Termijtelen A, de Vries RR, van Rood JJ, Giphart MJ.

Immunogenetics. 1988;27(1):40-5.

PMID:
3257099
12.

Cloned suppressor T cells from a lepromatous leprosy patient suppress Mycobacterium leprae reactive helper T cells.

Ottenhoff TH, Elferink DG, Klatser PR, de Vries RR.

Nature. 1986 Jul 31-Aug 6;322(6078):462-4.

PMID:
2426597
13.

Molecular, serologic, and functional evidence for an apparent HLA-DR triplet.

Bontrop RE, Schreuder GM, Elferink DG, Mikulski MM, Geerse R, Giphart MJ.

J Immunol. 1986 Jul 1;137(1):211-6.

PMID:
3486913
14.

Mycobacterium leprae-specific protein antigens defined by cloned human helper T cells.

Ottenhoff TH, Klatser PR, Ivanyi J, Elferink DG, de Wit MY, de Vries RR.

Nature. 1986 Jan 2-8;319(6048):66-8.

PMID:
2417123
15.

HLA class II restriction repertoire of antigen-specific T cells. II. Evidence for a new restriction determinant associated with DRw52 and LB-Q1.

Ottenhoff TH, Elferink DG, Termijtelen A, Koning F, de Vries RR.

Hum Immunol. 1985 Jun;13(2):117-23.

PMID:
2409061
17.

Unresponsiveness to Mycobacterium leprae in lepromatous leprosy in vitro: reversible or not?

Ottenhoff TH, Elferink DG, de Vries RR.

Int J Lepr Other Mycobact Dis. 1984 Sep;52(3):419-24. No abstract available.

PMID:
6384079

Supplemental Content

Loading ...
Support Center